Hepatitis C
Conditions
Keywords
Chronic, Cognition Disorders, Neurocognition Disorders, Cognitive Impairments, Diffusion Magnetic Resonance Imaging, MRI functional, Verbal fluency
Brief summary
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function after treatment with Direct-acting Antivirals (DAAs).
Detailed description
Design: Prospective interventional study. Chronic HCV infected patients who are going to initiate a DAA-based antiviral regimen according to clinical practice will be recruited to participate in the study. Patients will be treated according to the current national and international guidelines for the treatment of HCV chronic hepatitis. The participation in the study will not influence neither the indication for de treatment nor the type of treatment prescribed. The only intervention in this study refers to the performance of extraordinary neuro-psychological evaluations and MRI studies at different times along the study. Patients and methods: This study will be performed in a cohort of 80 patients with CHC (≤ F3). The number of subjects required to test effects with sufficient power over the entire cortex varies between cortical measures (cortical thickness: N=39, surface area: N=21, volume: N=81; 10mm smoothing, power=0.8, α =0.05). For subcortical regions this number is between 16 and 76 subjects, depending on the region (Liem et al., 2015). Sample size calculations performed for functional magnetic resonance using values of medium Cohen's d effect size of 0.6 and 0.7 yield sample sizes of 88, 66 respectively to achieve 80% power at a significance level of 0.05 (Guo et al., 2012). Therefore, the sample size estimated in this project would yield enough power to detect small and medium effects size. The following studies will be conducted: 1. \- Cognitive assessment: The assessment with widely-used neuropsychological test batteries may yield summary scores for the domains: attention and reaction time (Continuous Performance Test (CPT), working memory (digits forward and backward WAIS-III subtest), information processing speed (digit symbol WAIS-III subtest and Trail making test Part A), verbal fluency (letter FAS and category animals subtest), learning and memory (Rey Auditory 2.- Verbal Learning Test (RAVLT) and Rey Copy Figure(RCF)), motor functioning (Grooved Pegboard) and executive functions (Tower of London, Trail making test Part B and Stroop color-word test). 2. \- MRI scanning: Imaging data will be acquired at the neurorradiology section of the Hospital Marques de Valdecilla, on a 3T MRI scanner (Achieva, Philips Medical Systems, Best, The Netherlands) at the Neuroradiology Department of Marques de Valdecilla University Hospital. Subjects will undergo a 30 minutes protocol that will include a high resolution T1- weighted image, a 64 directions DWI sequence and A BOLD resting state fMRI sequence. 3. \- MRI data analysis: It will involve structural, diffusion and functional MRI analyses. These analyses will be conducted by Neuroimaging Platform at the IDIVAL. 3.1.- Structural MRI: we will use the software FreeSurfer (http://freesurfer.net/) to quantify the volume of subcortical structures (amygdala, hippocampus, thalamus, putamen, globus pallidus, and caudate nucleus) and the area, thickness, and volume of 34 cortical structures (Desikan-Killiany atlas). 3.2.- Diffusion MRI: we will use FSL's TBSS and Probtracx tools http://www.fmrib.ox.ac.uk/fsl/index.html) to compare fractional anisotropy values (a measure based on restricted movement of water molecules) in whole brain voxelwise analysis and identify regions (clusters) where white matter is more disorganized. Also we will perform fiber tracking and study connectivity between different brain areas. 3.3.- Functional MRI (fMRI): resting state fmri will be used to evaluate regional interactions that occur when non performing and specific task. This analysis will be carried out with using SPM software http://www.fil.ion.ucl.ac.uk/spm/) and the toolbox PRONTO (http://www.mlnl.cs.ucl.ac.uk/pronto ).
Interventions
OTHERNeuropsychological evaluation and Brain MRI
This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times. Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging. Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1) (1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336.
Sponsors
Ministerio de Economía y Competitividad, Spain
Instituto de Investigación Marqués de Valdecilla
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* CHC patients 18-75 years old * Liver fibrosis ≤ F3 in Fibroscan/liver biopsy * Naive or previous failure to a treatment * Accept the study and sign the CI
Exclusion criteria
* Does not meet the above criteria * VIH or other viral coinfection * Hepatocarcinoma * Other systemic inflammatory diseases (i.e. RA, etc) * Neurodegenerative diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Continuous Performance Test (CPT) score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Cognitive impairment, particularly Attention and reaction time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Digits forward and backward WAIS-III subtest scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Cognitive impairment, particularly Working memory |
| Changes in Digit symbol WAIS-III subtest score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Information processing speed |
| Changes in Trail Making Test (TMT) Parts A & B scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Information processing speed |
| Changes in Letter FAS score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Verbal fluency |
| Changes in animal category subtest score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Verbal fluency |
| Changes in Rey Auditory Verbal Learning Test (RAVLT) scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Learning and memory |
| Changes in Rey Copy Figure(RCF) scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Learning and memory |
| Changes in cortical surface área assessed by MRI | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). |
| Changes in Tower of London score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Executive functions |
| Changes in Stroop color-word test scores | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Executive functions |
| Changes in cortical thickness | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). |
| Changes in cortical surface volumen assessed by MRI | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Basal Neuroimaging findings in HCV infected patients and changes after DAA treatment (Assesed through structural, diffusion and functional MRI). |
| Sustained Viral Response | 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Data on efficacy of treatments |
| Advers events | up to 24 weeks | Data on safety |
| Changes in Grooved Pegboard score | Basal and 3, 6 and 12 months after the end of treatment (Sustained Viral Response) | Neuropsychological test to assess Motor functioning |
Countries
Spain
Contacts
Primary ContactJavier Crespo García, MDPhD
Backup ContactBenedicto Crespo Facorro, MDPhD
Outcome results
None listed